<DOC>
	<DOCNO>NCT00423332</DOCNO>
	<brief_summary>Cediranib test assess effectiveness growth kidney cancer tumour also well tolerate .</brief_summary>
	<brief_title>Cediranib ( AZD2171 , RECENTINâ„¢ ) Metastatic Recurrent Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<criteria>Confirmation metastatic recurrent renal cell carcinoma Certain type previous anticancer therapy Renal Cell Carcinoma Patients type I insulindependent diabetes poorlycontrolled type II insulinindependent diabetes Patients history poorly control high blood pressure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>cancer</keyword>
	<keyword>tumour</keyword>
	<keyword>advanced cancer</keyword>
	<keyword>Metastatic renal cell carcinoma</keyword>
	<keyword>kidney cancer</keyword>
	<keyword>RECENTIN</keyword>
</DOC>